Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15766MR)

This product GTTS-WQ15766MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15766MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10270MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ133MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ7311MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ9576MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ15616MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VAY-736
GTTS-WQ9923MR IVTScrip™ mRNA-Anti-EPHA3, KB-004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-004
GTTS-WQ9562MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ2182MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW